Relapsed / refractory (R/R) Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) patients have a poor prognosis. No standard of care has been established for relapsed / refractory ALL, and thus treatment remains a challenge. The mainstay of therapy is chemotherapy such as that used in the first line. The approval of therapies such as Amgen’s Blincyto, Pfizer’s Besponsa, and the CD19-targeted CAR T-cell therapies Kymriah (Novartis) and Tecartus (Kite Pharma / Gilead Sciences) have expanded the treatment options, but these agents rarely lead to a cure and are associated with potentially severe side effects. Therefore, a strong need remains for more-efficacious and well-tolerated treatments that improve patients’ outcomes.
QUESTIONS ANSWERED
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 30 European hematologist-oncologists fielded in February 2024
Key drugs: Blincyto, Besponsa, Kymriah, Tecartus
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
KEY FEATURE
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.